{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:25:34Z","timestamp":1792481134367,"version":"4.5.0"},"reference-count":14,"publisher":"Japan Society for Clinical Immunology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2177\/jsci.40.95","type":"journal-article","created":{"date-parts":[[2017,6,11]],"date-time":"2017-06-11T22:15:06Z","timestamp":1497219306000},"page":"95-101","source":"Crossref","is-referenced-by-count":32,"title":["Varied immuno-related adverse events induced by immune-check point inhibitors \u2014 Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6 \u2014"],"prefix":"10.2177","volume":"40","author":[{"given":"Naoko","family":"OKIYAMA","sequence":"first","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, University of Tsukuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"TANAKA","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, University of Tsukuba"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) Ryder, M., et al.: Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. <i>Endocr Relat Cancer<\/i>. <b>21<\/b>: 371-381, 2014."},{"key":"2","unstructured":"2) Tanaka, R., et al.: Nivolumab-induced thyroid dysfunction. <i>Jpn J Clin Oncol<\/i>. <b>46<\/b>: 575-579, 2016."},{"key":"3","unstructured":"3) Tanaka, R., et al.: Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report. <i>Jpn J Clin Oncol<\/i>. <b>46<\/b>: 875-878, 2016."},{"key":"4","unstructured":"4) Liao, B., et al.: Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. <i>Neuro Oncol<\/i>. <b>16<\/b>: 589-593, 2014."},{"key":"5","unstructured":"5) Conry, R.M., et al.: Ipilimumab-induced encephalopathy with a reversible splenial lesion. <i>Cancer Immunol Res<\/i>. <b>3<\/b>: 598-601, 2015."},{"key":"6","unstructured":"6) Mandel, J.J., et al.: Lambrolizumab induced central nervous system (CNS) toxicity. <i>J Neurol Sci<\/i>. <b>344<\/b>: 229-231, 2014."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tanaka, R., et al.: Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-alpha is a biomarker of nivolumab recativity. <i>J Dermatol Sci<\/i>, 2016.","DOI":"10.1016\/j.jdermsci.2016.12.019"},{"key":"8","unstructured":"8) Matsumura, N., et al.: Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma. <i>Acta Derm Venereol<\/i>. <b>96<\/b>: 259-260, 2016."},{"key":"9","unstructured":"9) Kato, Y., et al.: Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. <i>J Eur Acad Dermatol Venereol<\/i>. <b>30<\/b>: e89-e91, 2016."},{"key":"10","unstructured":"10) Murata, S., et al.: Case of de novo psoriasis possibly triggered by nivolumab. <i>J Dermatol<\/i>. <b>44<\/b>: 99-100, 2017."},{"key":"11","unstructured":"11) Law-Ping-Man, S., et al.: Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. <i>Rheumatology (Oxford)<\/i>. <b>55<\/b>: 2087-2089, 2016."},{"key":"12","unstructured":"12) Chia, P.L., John, T.: Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>J Immunother<\/i>. <b>39<\/b>: 202-204, 2016."},{"key":"13","unstructured":"13) Dulos, J., et al.: PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer. <i>Journal of Immunotherapy<\/i>. <b>35<\/b>: 169-178, 2012."},{"key":"14","unstructured":"14) Watanabe, H., et al.: Functional Characterization of IL-17F as a Selective Neutrophil Attractant in <i>Psoriasis. J Invest Dermatol<\/i>. <b>129<\/b>: 650-656, 2009."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306b\u3088\u3063\u3066\u8a98\u767a\u3055\u308c\u308b\u591a\u5f69\u306a\u81ea\u5df1\u514d\u75ab\u53cd\u5fdc\u6027\u526f\u4f5c\u7528 \u2014 interleukin-6\u3092\u4ecb\u3059\u308b\u4e7e\u766c\u69d8\u76ae\u819a\u708e\u3092\u4e2d\u5fc3\u306b \u2014"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/40\/2\/40_95\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T22:17:42Z","timestamp":1569449862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/40\/2\/40_95\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.40.95","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}